President and CEO of Bio-Techne, Kim Kelderman, commented on the results, acknowledging the team’s resilience in a challenging environment. He expressed optimism regarding the stabilization observed in China and reiterated confidence in the company’s long-term growth prospects. Kelderman also expressed…
Roche (SIX: RO, ROG; OTCQX: RHHBY) has revealed the findings from Stage 1 of the National Institutes of Health (NIH)-sponsored pivotal Phase III OUtMATCH study, assessing the effectiveness and safety of Xolair® (omalizumab) in patients with peanut allergies and allergies…
Celltrion presented encouraging findings from the extensive LIBERTY studies, including LIBERTY-CD 1 and LIBERTY-UC 2, focusing on patients with Alzheimer’s disease, Crohn’s disease (CD), or moderately to severely active ulcerative colitis (UC). Additionally, the company shared endoscopic results from a…
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a company specializing in gastrointestinal healthcare, has revealed plans to present findings from four studies examining apraglutide in adults diagnosed with short bowel syndrome with intestinal failure (SBS-IF), a condition where individuals rely on parenteral…
Celltrion Healthcare Canada Limited has announced today that Health Canada has granted approval for Remsima™ SC as maintenance therapy for adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD). Remsima™ SC, a subcutaneous form of infliximab,…
AbbVie has revealed that 17 AbbVie-sponsored abstracts, featuring fresh insights from its inflammatory bowel disease (IBD) portfolio, have been accepted for showcase at the 19th Congress of European Crohn’s and Colitis Organisation (ECCO) in Stockholm, Sweden from February 21-24. Included…
The COVID-19 pandemic has brought to light the vulnerabilities inherent in global supply chains, especially affecting the access of low- and middle-income countries (LMICs) to crucial medical supplies. The disproportionate concentration of manufacturing capacity in a handful of nations and…
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a pioneer in precision genetic medicine for rare diseases, has announced today that the U.S. Food and Drug Administration (FDA) has accepted and filed the Company’s efficacy supplement to the Biologics License Application (BLA) for…
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) has revealed that the anti-CD20/CD3 bispecific antibody mosunetuzumab has successfully met the primary endpoint of achieving a complete response rate (CRR) in an expansion cohort within the Japanese Phase I study. This study aimed…
Encouraging Outcomes in Japan Phase III Trial of Acoramidis for Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) Consistent with Global ATTRibute-CM Phase III Trial Positive high-level results from the Japan Phase III trial of acoramidis in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) showed…
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new 72-week data from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo® (faricimab) in macular edema due to branch and central retinal vein occlusion (BRVO and CRVO).1,2 Whereas available RVO treatments are…
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, and Pierre Fabre Laboratories, a global player in oncology and responsible for worldwide…